# The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine

> **NCT05273528** · PHASE2 · UNKNOWN · sponsor: **Livzon Pharmaceutical Group Inc.** · enrollment: 20 (actual)

## Conditions studied

- COVID-19 Pandemic

## Interventions

- **BIOLOGICAL:** Recombinant SARS-CoV-2 Beta Variant Fusion Protein Vaccine/Recombinant SARS-CoV-2 Delta Variant Fusion Protein Vaccine

## Key facts

- **NCT ID:** NCT05273528
- **Lead sponsor:** Livzon Pharmaceutical Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-11
- **Primary completion:** 2023-01-06
- **Final completion:** 2023-01-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05273528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05273528, "The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05273528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*